{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:35:03Z","timestamp":1794746103844,"version":"4.9.1"},"reference-count":26,"publisher":"American Society of Hematology","issue":"2","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,28]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>We analyzed access\u00a0barriers to anti-CD19+\u00a0chimeric antigen receptor T cells (CARTs) for non-Hodgkin lymphoma (NHL) within a community-based transplant and cell therapy network registry. A total of 357 intended recipients for approved anti-CD19+\u00a0CARTs were identified\u00a0between 2018 to 2022.\u00a0The median age at referral was 61 years; referral years were 2018 (4%), 2019 (14%), 2020 (18%), 2021 (26%), and 2022 (38%). Diagnoses included diffuse large B cell (69%), follicular (13%), follicular\/large (7%), mantle cell (4%), or other (7%).\u00a0Axicabtagene ciloleucel (62%), tisagenlecleucel (16%), brexucabtagene autoleucel (13%), and lisocabtagene maraleucel (9 %) were infused into 182 patients. The median durations between referral to consultation, consultation to apheresis, and collection to infusion were 11, 107, and 32\u00a0days, respectively. The median duration from consultation to CART infusion declined steadily from 207\u00a0days in 2019 to 108\u00a0days in 2022 (P\u00a0&amp;lt; .0001). A total of 124 patients (41%) did not receive CART, mostly for disease progression (34%) or poor health (15%). Multivariable logistic regression showed no significant differences in demographic, financial, or social determinants compared with those receiving CART. Notably, the proportion of ineligible patients declined from 53% in 2018-2020 to 34% by 2021-2022 (P\u00a0=\u00a0.001). In conclusion, 41% of community patients were unable to access timely CART therapy, mostly due to attrition from disease-related causes, and the overall time to infusion exceeded 4\u00a0months. Time to infusion and the proportion receiving CARTs improved over time. Reducing time to apheresis, early referral, and attention to salvage\/bridging strategies are necessary.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014171","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T19:45:46Z","timestamp":1729194346000},"page":"429-435","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network"],"prefix":"10.1182","volume":"9","author":[{"given":"Minoo","family":"Battiwalla","sequence":"first","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"},{"name":"2Tristar Centennial Medical Center, HCA Healthcare, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tees","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"},{"name":"3Presbyterian\/St. Luke\u2019s Medical Center and Colorado Blood Cancer Institute, HCA Healthcare, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-290X","authenticated-orcid":false,"given":"Ian","family":"Flinn","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"},{"name":"2Tristar Centennial Medical Center, HCA Healthcare, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Pantin","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"},{"name":"2Tristar Centennial Medical Center, HCA Healthcare, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0376","authenticated-orcid":false,"given":"Jesus","family":"Berdeja","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"},{"name":"2Tristar Centennial Medical Center, HCA Healthcare, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Gregory","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"},{"name":"3Presbyterian\/St. Luke\u2019s Medical Center and Colorado Blood Cancer Institute, HCA Healthcare, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maris","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"},{"name":"3Presbyterian\/St. Luke\u2019s Medical Center and Colorado Blood Cancer Institute, HCA Healthcare, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Bhushan","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"},{"name":"4Medical City Dallas Hospital and Texas Oncology, HCA Healthcare, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estil","family":"Vance","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"},{"name":"4Medical City Dallas Hospital and Texas Oncology, HCA Healthcare, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mathews","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"},{"name":"4Medical City Dallas Hospital and Texas Oncology, HCA Healthcare, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Bachier","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"},{"name":"5Methodist Hospital, HCA Healthcare, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"},{"name":"5Methodist Hospital, HCA Healthcare, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"},{"name":"6St. David\u2019s South Austin Medical, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahbaz","family":"Malik","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"},{"name":"6St. David\u2019s South Austin Medical, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Mori","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"},{"name":"7MountainView Hospital, Las Vegas, NV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Martin","sequence":"additional","affiliation":[{"name":"8Genospace, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocky","family":"Billups","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Blunk","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2462-0186","authenticated-orcid":false,"given":"Charles F.","family":"LeMaistre","sequence":"additional","affiliation":[{"name":"1Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-891X","authenticated-orcid":false,"given":"Navneet S.","family":"Majhail","sequence":"additional","affiliation":[{"name":"2Tristar Centennial Medical Center, HCA Healthcare, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"issue":"23","key":"2025012816202828900_bib1","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1182\/bloodadvances.2022008106","article-title":"Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL","volume":"6","author":"Abramson","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"2025012816202828900_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.16685","article-title":"Upsetting the apple CAR-T (chimeric antigen receptor T-cell therapy) - sustainability mandates USA innovation","volume":"190","author":"Pantin","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"2025012816202828900_bib3","first-page":"163","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"issue":"7","key":"2025012816202828900_bib4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","article-title":"Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"29","author":"Hoffmann","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2025012816202828900_bib5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2025012816202828900_bib6","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"2025012816202828900_bib7","unstructured":"Foundation for the Accreditation of Cellular Therapy\n          . USA IECT Center List. FACT Accredited Institutions. Accessed 12 September 2023. https:\/\/accredited.factglobal.org\/."},{"issue":"10","key":"2025012816202828900_bib8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2217\/imt-2020-0118","article-title":"Perceptions of community hematologists\/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma","volume":"12","author":"Gajra","year":"2020","journal-title":"Immunotherapy"},{"issue":"suppl 1","key":"2025012816202828900_bib9","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1182\/blood-2021-151807","article-title":"CAR T therapy referral for diffuse large B cell lymphoma (DLBCL) by U.S. Community Hematology\/Oncology (cH\/O) practices: perceptions and patterns","volume":"138","author":"Porter","year":"2021","journal-title":"Blood"},{"key":"2025012816202828900_bib10","doi-asserted-by":"crossref","first-page":"100913","DOI":"10.1016\/j.blre.2021.100913","article-title":"Reality check: real-world evidence to support therapeutic development in hematologic malignancies","volume":"53","author":"Derman","year":"2022","journal-title":"Blood Rev"},{"issue":"21","key":"2025012816202828900_bib11","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2025012816202828900_bib12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.36401\/JIPO-21-2","article-title":"Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: how similar are they to the prospective studies?","volume":"4","author":"Tang","year":"2021","journal-title":"J\u00a0Immunother Precis Oncol"},{"issue":"7","key":"2025012816202828900_bib13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"2025012816202828900_bib14","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world evidence of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"issue":"26","key":"2025012816202828900_bib15","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMp1802313","article-title":"Making neighborhood-disadvantage metrics accessible - the neighborhood atlas","volume":"378","author":"Kind","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2025012816202828900_bib16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2105\/AJPH.93.7.1137","article-title":"Area deprivation and widening inequalities in US mortality, 1969-1998","volume":"93","author":"Singh","year":"2003","journal-title":"Am J Public Health"},{"issue":"2 Pt 1","key":"2025012816202828900_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1475-6773.2012.01449.x","article-title":"Measures of social deprivation that predict health care access and need within a rational area of primary care service delivery","volume":"48","author":"Butler","year":"2013","journal-title":"Health Serv Res"},{"key":"2025012816202828900_bib18","unstructured":"United States Sensus Burreau\n          . US census data. Accessed 13 August 2024. https:\/\/www.census.gov\/data.html."},{"key":"2025012816202828900_bib19","doi-asserted-by":"crossref","first-page":"1121030","DOI":"10.3389\/fimmu.2023.1121030","article-title":"Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells","volume":"14","author":"Hiltensperger","year":"2023","journal-title":"Front Immunol"},{"issue":"24","key":"2025012816202828900_bib20","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1111\/jcmm.17550","article-title":"Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: a real-world study","volume":"26","author":"Iovino","year":"2022","journal-title":"J\u00a0Cell Mol Med"},{"issue":"6","key":"2025012816202828900_bib21","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3390\/cancers15061747","article-title":"Long-term follow-up of bridging therapies prior to CAR T-cell therapy for relapsed\/refractory large B cell lymphoma","volume":"15","author":"Ladbury","year":"2023","journal-title":"Cancers"},{"issue":"27","key":"2025012816202828900_bib22","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2025012816202828900_bib23","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1377\/hlthaff.2022.01406","article-title":"The neighborhood atlas area deprivation index for measuring socioeconomic status: an overemphasis on home value","volume":"42","author":"Hannan","year":"2023","journal-title":"Health Aff"},{"issue":"10","key":"2025012816202828900_bib24","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/bloodadvances.2023011996","article-title":"Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy","volume":"8","author":"Karmali","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"2025012816202828900_bib25","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"suppl_1","key":"2025012816202828900_bib26","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood-2019-124750","article-title":"Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US)","volume":"134","author":"Pasquini","year":"2019","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/2\/429\/2353191\/blooda_adv-2024-014171-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/2\/429\/2353191\/blooda_adv-2024-014171-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T16:20:49Z","timestamp":1738081249000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/2\/429\/518217\/Access-barriers-to-anti-CD19-CART-therapy-for-NHL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014171","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]}}}